TY - JOUR
T1 - Proposed preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after surgical resection
T2 - A multi-center retrospective study
AU - Matsumoto, Ippei
AU - Murakami, Yoshiaki
AU - Shinzeki, Makoto
AU - Asari, Sadaki
AU - Goto, Tadahiro
AU - Tani, Masaji
AU - Motoi, Fuyuhiko
AU - Uemura, Kenichiro
AU - Sho, Masayuki
AU - Satoi, Sohei
AU - Honda, Goro
AU - Yamaue, Hiroki
AU - Unno, Michiaki
AU - Akahori, Takahiro
AU - Kwon, A. Hon
AU - Kurata, Masanao
AU - Ajiki, Tetsuo
AU - Fukumoto, Takumi
AU - Ku, Yonson
N1 - Publisher Copyright:
© 2015 IAP and EPC.
PY - 2015
Y1 - 2015
N2 - Background/objective Although surgical resection remains the only chance for cure in patients with pancreatic ductal adenocarcinoma (PDAC), postoperative early recurrence (ER) is frequently encountered. The purpose of this study is to determine the preoperative predictive factors for ER after upfront surgical resection. Methods Between 2001 and 2012, 968 patients who underwent upfront surgery with R0 or R1 resection for PDAC at seven high-volume centers in Japan were retrospectively reviewed. ER was defined as relapse within 6 months after surgery. Study analysis stratified by resectable (R) and borderline resectable (BR) PDACs was conducted according to the National Comprehensive Cancer Network guidelines. Results ER occurred in 239 patients (25%) with a median survival time (MST) of 8.8 months. Modified Glasgow prognostic score = 2 (odds ratio (OR) 2.06, 95% confidence interval (CI) 1.05-3.95; P = 0.044), preoperative CA19-9 ≥300 U/ml (OR 1.94, 1.29-2.90; P = 0.003), and tumor size ≥30 mm (OR 1.72, 1.16-2.56; P = 0.006), were identified as preoperative independent predictive risk factors for ER in patients with R-PDAC. In the R-PDAC patients, MST was 35.5, 26.3, and 15.9 months in patients with 0, 1 and ≥2 risk factors, respectively. There were significant differences in overall survival between the three groups (P < 0.001). No preoperative risk factors were identified in BR-PDAC patients with a high rate of ER (39%). Conclusions There is a high-risk subset for ER even in patients with R-PDAC and a simple risk scoring system is useful for prediction of ER.
AB - Background/objective Although surgical resection remains the only chance for cure in patients with pancreatic ductal adenocarcinoma (PDAC), postoperative early recurrence (ER) is frequently encountered. The purpose of this study is to determine the preoperative predictive factors for ER after upfront surgical resection. Methods Between 2001 and 2012, 968 patients who underwent upfront surgery with R0 or R1 resection for PDAC at seven high-volume centers in Japan were retrospectively reviewed. ER was defined as relapse within 6 months after surgery. Study analysis stratified by resectable (R) and borderline resectable (BR) PDACs was conducted according to the National Comprehensive Cancer Network guidelines. Results ER occurred in 239 patients (25%) with a median survival time (MST) of 8.8 months. Modified Glasgow prognostic score = 2 (odds ratio (OR) 2.06, 95% confidence interval (CI) 1.05-3.95; P = 0.044), preoperative CA19-9 ≥300 U/ml (OR 1.94, 1.29-2.90; P = 0.003), and tumor size ≥30 mm (OR 1.72, 1.16-2.56; P = 0.006), were identified as preoperative independent predictive risk factors for ER in patients with R-PDAC. In the R-PDAC patients, MST was 35.5, 26.3, and 15.9 months in patients with 0, 1 and ≥2 risk factors, respectively. There were significant differences in overall survival between the three groups (P < 0.001). No preoperative risk factors were identified in BR-PDAC patients with a high rate of ER (39%). Conclusions There is a high-risk subset for ER even in patients with R-PDAC and a simple risk scoring system is useful for prediction of ER.
KW - Early recurrence
KW - Multi-center study
KW - Pancreatic cancer
KW - Pancreatic ductal adenocarcinoma
KW - Preoperative risk factor
KW - Resectable pancreatic cancer
UR - http://www.scopus.com/inward/record.url?scp=84951826584&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84951826584&partnerID=8YFLogxK
U2 - 10.1016/j.pan.2015.09.008
DO - 10.1016/j.pan.2015.09.008
M3 - Article
C2 - 26467797
AN - SCOPUS:84951826584
SN - 1424-3903
VL - 15
SP - 674
EP - 680
JO - Pancreatology
JF - Pancreatology
IS - 6
ER -